Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381732 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
NCT00381732 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 280 participants.
The verdict
NCT00381732, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of 2.5mg and 5mg tadalafil taken once daily in men with erectile dysfunction.
Interventions
- DRUG placebo
- DRUG tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381732
The ClinicalTrials.gov registry entry for NCT00381732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00381732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381732 about?
NCT00381732 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction". This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of 2.5mg and 5mg tadalafil taken once daily in men with erectile dysfunction.
What is the current status of trial NCT00381732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2003-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00381732?
The interventions under investigation include: placebo (DRUG), tadalafil (DRUG).
Who is sponsoring clinical trial NCT00381732?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.